November 29, 2021

NasdaqNewsUpdates

Complete News World

EMA announces rapid review of Merck’s anti-govt pill

“The EMA Group for Human-Use Medicinal Products (CHMP) has begun a series of reviews of the oral antiviral drug Molnupravir (…) developed by Merck (…) for the treatment of Covit-19 in adults.

Preliminary results of laboratory and clinical studies suggest that the drug may reduce the body’s potential for SARS – CoV – 2 (…), thus preventing patients from being hospitalized or dying.

If approved, this drug, called molnupravir, would make great strides in reducing the more severe forms of the disease.

Antivirals such as molnupravir work by reducing the replication ability of the virus, thus reducing disease.

Given to patients within a few days of a positive test, treatment halves the risk of hospitalization and death, according to a clinical trial conducted by Merck, also known as MSD outside the United States.

EMA evaluates the compliance of molnupiravir with conventional European standards for efficacy, safety and quality.

See also  Italy: Former Prime Minister Conte takes over as leader of the 5 Star Movement